Advertisement

“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”

Published:September 09, 2022DOI:https://doi.org/10.1016/j.clgc.2022.09.005

      ABSTRACT

      MicroAbstract

      A panel of Brazilian experts convened in order to provide recommendations regarding staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up in non-metastatic, castration-resistant prostate cancer. Key points include the reliance on prostate-specific antigen doubling time for treatment decisions, the absence of a clear preference between conventional and novel imaging techniques, and the increasing role of novel androgen-receptor signaling inhibitors.

      Introduction

      Non-metastatic, castration-resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen-receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC. Given recent developments in this field, we update our recommendations for the management of nmCRPC.

      Methods

      A panel of 51 invited medical oncologists and urologists convened in May of 2021 with the aim of discussing and providing recommendations regarding the most relevant issues concerning staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up in nmCRPC. Panel members considered the available evidence and their practical experience to address the 73 multiple-choice questions presented.

      Results

      Key recommendations and findings include the reliance on prostate-specific antigen doubling time for treatment decisions, the absence of a clear preference between conventional and novel (i.e., positron-emission tomography-based) imaging techniques, the increasing role of ARSis in various settings, the general view that ARSis have similar efficacy. Panelists highlighted the slight preference for darolutamide, when safety is of greater concern, and a continued need to develop high-level evidence to guide the intensity of follow-up in this subset of prostate cancer.

      Discussion

      Despite the limitations associated with a consensus panel, the topics addressed are relevant in current practice, and the recommendations can help practicing clinicians to provide state-of-the-art treatment to patients with nmCRPC in Brazil and other countries with similar healthcare settings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021;
        • Mateo J
        • Fizazi K
        • Gillessen S
        • et al.
        Managing Nonmetastatic Castration-resistant Prostate Cancer.
        Eur Urol. 2019; 75: 285-293
        • Scher HI
        • Morris MJ
        • Stadler WM
        • et al.
        Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
        J Clin Oncol. 2016; 34: 1402-1418
        • Smith MR
        • Kabbinavar F
        • Saad F
        • et al.
        Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
        J Clin Oncol. 2005; 23: 2918-2925
        • Liede A
        • Arellano J
        • Hechmati G
        • Bennett B
        • Wong S.
        International prevalence of nonmetastatic (M0) castration resistant prostate cancer (CRPC).
        J Clin Oncol. 2013; 31 (suppl): e16052
        • Cornford P
        • van den Bergh RCN
        • Briers E
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
        Eur Urol. 2021; 79: 263-282
        • Smith MR
        • Cook R
        • Lee KA
        • Nelson JB.
        Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
        Cancer. 2011; 117: 2077-2085
        • Smith MR
        • Saad F
        • Oudard S
        • et al.
        Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
        J Clin Oncol. 2013; 31: 3800-3806
        • Scher HI
        • Solo K
        • Valant J
        • Todd MB
        • Mehra M.
        Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model.
        PLoS One. 2015; 10e0139440
        • Esther J
        • Dorff TB
        • Maughan BL.
        Recent developments in the treatment of non-metastatic castration resistant prostate cancer.
        Cancer Treat Res Commun. 2020; 24100181
        • Gupta R
        • Sheng IY
        • Barata PC
        • Garcia JA.
        Non-metastatic castration-resistant prostate cancer: current status and future directions.
        Expert Rev Anticancer Ther. 2020; 20: 513-522
        • Perera M
        • Papa N
        • Roberts M
        • et al.
        Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
        Eur Urol. 2020; 77: 403-417
        • Maluf F
        • Soares A
        • Avanco G
        • et al.
        Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.
        Int Braz J Urol. 2021; 47: 359-373
        • Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva
        Estimativa 2020: incidência de câncer no Brasil.
        INCA, Rio de Janeiro2019 (Available at) (Accessed 31 August 2021)
        • National Comprehensive Cancer Network
        NCCN Practice Guidelines in Oncology.
        Prostate Cancer – v.1. 2022; (Available at) (Accessed on 24 November 2021)
        • Hussain M
        • Fizazi K
        • Saad F
        • et al.
        Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
        N Engl J Med. 2018; 378: 2465-2474
        • Smith MR
        • Saad F
        • Chowdhury S
        • et al.
        Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
        N Engl J Med. 2018; 378: 1408-1418
        • Fizazi K
        • Shore N
        • Tammela TL
        • et al.
        Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
        N Engl J Med. 2019; 380: 1235-1246
        • Hofman MS
        • Lawrentschuk N
        • Francis RJ
        • et al.
        Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
        Lancet. 2020; 395: 1208-1216
        • Fendler WP
        • Weber M
        • Iravani A
        • et al.
        Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
        Clin Cancer Res. 2019; 25: 7448-7454
        • Crawford ED
        • Andriole G
        • Freedland SJ
        • et al.
        Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
        Can J Urol. 2020; 27: 10352-10362
        • Heidegger I
        • Brandt MP
        • Heck MM.
        Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?.
        Urol Oncol. 2020; 38: 129-136
        • Small EJ
        • Saad F
        • Chowdhury S
        • et al.
        Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
        Ann Oncol. 2019; 30: 1813-1820
        • Fizazi K
        • Shore N
        • Tammela TL
        • et al.
        Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
        N Engl J Med. 2020; 383: 1040-1049
        • Sternberg CN
        • Fizazi K
        • Saad F
        • et al.
        Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
        N Engl J Med. 2020; 382: 2197-2206
        • Basch E
        • Loblaw DA
        • Oliver TK
        • et al.
        Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
        J Clin Oncol. 2014; 32: 3436-3448
        • Buck SAJ
        • Koolen SLW
        • Mathijssen RHJ
        • de Wit R
        • van Soest RJ.
        Cross-resistance and drug sequence in prostate cancer.
        Drug Resist Updat. 2021; 56100761
        • Khalaf DJ
        • Annala M
        • Taavitsainen S
        • et al.
        Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
        Lancet Oncol. 2019; 20: 1730-1739
        • Pereira FMT
        • Silva AGE
        • Dettino ALA
        • et al.
        Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.
        JCO Glob Oncol. 2021; 7: 545-549
        • Saad F
        • Cella D
        • Basch E
        • et al.
        Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2018; 19: 1404-1416
        • Smith MR
        • Shore N
        • Tammela TL
        • et al.
        Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
        Eur J Cancer. 2021; 154: 138-146
        • Tombal B
        • Saad F
        • Penson D
        • et al.
        Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
        Lancet Oncol. 2019; 20: 556-569
        • Hird AE
        • Magee DE
        • Bhindi B
        • et al.
        A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
        Clin Genitourin Cancer. 2020; 18: 343-350
        • Kumar J
        • Jazayeri SB
        • Gautam S
        • et al.
        Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
        Urol Oncol. 2020; 38: 826-834
        • Mori K
        • Mostafaei H
        • Pradere B
        • et al.
        Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
        Int J Clin Oncol. 2020; 25: 1892-1900
        • Wenzel M
        • Nocera L
        • Colla Ruvolo C
        • et al.
        Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
        Prostate Cancer Prostatic Dis. 2021;
        • Graff JN
        • Beer TM.
        Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
        Oncology (Williston Park). 2015; 29: 416-423